herpes zoster
Conditions
Interventions
investigational material(s)
Generic name etc : ASP2151
INN of investigational material :
Therapeutic category code : 625 Anti-virus agents
Dosage and Administration for Investigational material : 200
Sponsors
Maruho Co.,Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who have a rash associated with herpes zoster, and who can start receiving the study drug within 72 hours after onset of the rash
Exclusion criteria
Exclusion criteria: (1) Patients who are not expected to have an adequate response to oral antiviral medication (2) An extreme decline in immune function (3) Presence of serious complications (4) Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent: 1) AST or ALT >= 2.5 x upper limit of normal 2) Platelet count = 1.5 mg/dL 4) Creatinine clearance < 50 mL/min (5) Current or previous history of malignant tumor within 5 years before informed consent (6) Diagnosis of autoimmune disease (7) Evidence of bone marrow suppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects achieving cessation of new lesion formation by Day 4 of study treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to cessation of new lesion formation, time to complete crusting, time to healing, time to pain resolution, and time to virus disappearance | — |
Outcome results
None listed